PERSPECTA

News from every angle

← Back to headlines

AstraZeneca Q2 Non-GAAP EPS tops expectations by $1.36; reconfirms full-year outlook

AstraZeneca has maintained its full-year outlook after reporting a profit beat in the second quarter, driven by strong sales of its cancer and rare disease drugs, with non-GAAP EPS topping expectations by $1.36.

27 Jul, 07:15 — 27 Jul, 07:15
PostShare

Sources

Showing 1 of 2 sources
seeking-alphaMixed12d ago

AstraZeneca Q2 Non-GAAP EPS tops expectations by $1.36; reconfirms full-year outlook

Read full article →

Coverage Timeline

First report: seeking-alpha · 27 Jul, 07:15Full coverage: 2 · 4mWindow: 4m
Left-leaningCenterRight-leaning
seeking-alpha27 Jul, 07:15First to report

AstraZeneca Q2 Non-GAAP EPS tops expectations by $1.36; reconfirms full-year outlook

Yahoo27 Jul, 07:19Latest update

AstraZeneca maintains outlook as cancer, rare disease drugs drive profit beat

Related Stories

Nigeria and China Deepen Agricultural Partnership

11m ago

US Senate's Russia Sanctions Bill Faces Hurdles

30m ago

Pagadian's 'Salt Sisters' Revive Traditional Salt Industry

41m ago

After-Tax Portfolio Income Comparison: Florida vs. New York

49m ago